|

QL2109 or Daratumumab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Qilu Pharmaceutical Co., Ltd.1

Indications

  • Relapsed or Refractory Multiple Myeloma1
  • Cancer1

Other1 trial

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.